Tuesday, November 25, 2008
WallSt TV Interviews Kenneth Aldrich
Posted by PSEO at 11:54 AM
Labels: biotechnology, international stem cell, kenneth aldrich, parthenogenesis, stem cell, WallSt TV
Posted by PSEO at 11:54 AM
Labels: biotechnology, international stem cell, kenneth aldrich, parthenogenesis, stem cell, WallSt TV
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for the company and its subsidiary, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.
-30-